Skip to main content

BGI, Merck Agree to Explore Areas of Interest in Next-gen Sequencing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BGI today announced that it has signed a statement of intent with drug giant Merck to explore areas of mutual interest with the goal of "creating value" from the high volume of information resulting from next-generation sequencing technologies.

In a statement, Peter Kim, president of Merck Research Laboratories, said the statement of intent is the first step toward bringing together his firm's expertise in pharmaceutical development "with the powerful sequencing and bioinformatics capabilities of BGI."

The deal creates principles of cooperation for the partners in order to develop separate master agreements and projects, and includes establishing mutual offices near each other in the US and in China "to enable closer collaboration between scientists from both companies."

The partners intend to build an infrastructure that will support collaboration in areas such as biomarkers, target validation, and drug de-risking and development.

Three weeks ago, BGI and the University of Copenhagen signed an agreement to cooperate together on genetic research into cancer, obesity, and type 2 diabetes.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.